Background: Pleomorphic xanthoastrocytoma is a rare tumour of children and young adults, particularly for those with features of anaplasia. Materials and Methods: This retrospective study comprises five cases of anaplastic pleomorphic xanthoastrocytomas diagnosed over a period of 4 years in a tertiary care institute.
INTRODUCTION
Pleomorphic xanthoastrocytoma (PXA) is a rare tumour of children and constitutes less than 1% of all astrocytic glial neoplasms 1, 2 . PXA is a World Health Organisation (WHO) grade II tumour with favourable prognosis 3 . It is now known that 15 . Anaplastic PXA (APXA) is either primary i.e. de novo or secondary i.e. anaplastic transformation in recurrent conventional PXA 4 . APXA has a poor prognosis and rarely can undergo transformation to glioblastoma 5 . All the cases of APXA were evaluated for their clinicoradiological, histomorphological and immunohistochemical (IHC) findings.
MATERIALS AND METHODS
This retrospective study included 5 cases of APXAs diagnosed over a period of 4 years (January 2012 to December 2016) in a tertiary care institute. A detailed clinicopathological and IHC profile of the tumours were noted from the hospital database. All the samples were fixed in 10% neutral buffered formalin and embedded in paraffin. Staining was done with haematoxylin and eosin. The archival hematoxylin and eosin slides were reviewed by the authors. IHC staining for monoclonal antibodies Glial Fibrillary Acid Protein (GFAP), S 100, Neuron Specific Enolase (NSE), CD 34, Synaptophysin and Ki67 were done by Avidin Biotin peroxidase method with pre-treatment by microwave heating. All histopathological slides made from the paraffin blocks and submitted to the department of pathology were reviewed in this study. Informed consent was obtained from the patents or their relatives for use of data for publication purpose. As this retrospective study had no interventions other than the standard care, permission from the institutional review board was not obtained.
RESULTS
There were 5 cases of APXA diagnosed based on histopathological and immunohistochemical findings. The age of the patients ranged from 11 years to 40 years with a mean age of 22 years. There were 3 females and 2 males with M: F ratio of 3:2. All the 5 patients had varied clinical presentations with duration of symptoms ranging from 1 week to 1 month. The sites and the corresponding clinicoradiological diagnosis are summarised in Table 1 . 
Case 3
A 40-year-old female presented with complaints of urinary incontinence and vomiting for one week. On MRI, a well-circumscribed, contrast enhancing, dural-based mass measuring 6x5cm in the left temporal was seen. Craniotomy was done. Intraoperatively the tumour was found to be very vascular. The tumour was completely excised. Histomorphologic examination and immunohistochemistry findings are summarised in Table 2 .
Case 4
A 19-year-old male presented with headache and two episodes of generalised tonic clonic seizures over one month. On examination the vitals were found to be stable. He was conscious and oriented. There were no focal neurological deficits. MRI highlighted a cystic lesion with enhancing nodular component measuring 5X5 cm within the right frontal area near the motor cortex. Craniotomy and decompression of lesion were performed. Histomorphologic examination and immunohistochemistry findings are summarised in Table 2 .
Case 5
An 18-year-old female presented with repeated vomiting, headache, weakness of right upper limb and slurring of speech. MRI showed a left frontoparietal mass with midline shift. Fronto-parietal craniotomy and excision of the tumour were done with a pre-operative diagnosis of high grade glioma. Histomorphologic examination and immunohistochemistry findings are summarised in Table 2 Two years post-operatively, she came back with similar complaints and a repeat mass in the same site was found. Repeat biopsy showed highly cellular tumour with moderate to marked nuclear atypia and pleomorphism, markedly increased mitoses of 1-2 per high power field (HPF), focal microvascular proliferation and necrosis. GFAP was found to be positive along with 40% Ki67 and strong p53 positive in more than 90% of tumour cells. A diagnosis of malignant transformation to glioblastoma in a known case of pleomorphic xanthoastrocytoma with features of anaplasia was made. After one-year follow-up, the patient showed spinal metastasis.
Clinical follow-up
All the patients were on routine follow-up after the standard modalities of treatment for more than one year post-operatively. They were all disease-free except one patient (Case 5) who developed a malignant transformation to glioblastoma (WHO grade IV) with evidence of spinal metastasis after one year post surgery.
DISCUSSION
PXA, since its first description in 1979, has received scant documentation in the medical literature. This holds true particularly for those with the features of anaplasia 1 . It is known to be a tumour of the children, though exceptions are known 2, 4, 6 . Initially this entity was believed to be of astrocytic origin. However, of late, there has been a change in the understanding of the nature of these tumours. According to the available data, it has been proposed to be a developmental tumour of multipotent ectodermal origin, displaying neuronal differentiation and CD 34 positivity with a related, albeit focal, cortical dysplasia. The latter has been portrayed by the persistence of seizures despite complete surgery 7, 8 . Based on immunohistochemical and electron microscopic studies by various authors, they seem to represent the connecting link between developmental abnormalities and ganglionic tumours of the well- . There is a need to accurately diagnose this astrocytoma, for on one hand it can mimic other entities based on the location and morphology, posing a diagnostic dilemma, and, on the other hand, it can show anaplasia and aggressive behaviour in the form of recurrences and malignant transformation 2, 4, 11 . APXAs are believed to show the interphase between the lipidized giantcell glioblastoma and PXA 12 . Documented mortality in PXA ranges from 15 to 20% 13 . The anaplastic features have been found to be particularly of poor prognosis 5 . The latter has been described as those which show necrosis, cellular anaplasia which is severe, proliferating microvasculature, brisk mitosis (≥5 mitosis/10 high power fields) and increased Ki-67 labelling index 3, 5 .
As shown by the present study and those by Tonn et al., Sharma et al., and Ng et al., these patients typically present at a young age, though exceptional cases of elderly patients do occur 4, 6, 14 . Contrary to the typical clinical presentation of PXAs with seizures and cortical lesions, the cases in this series of anaplastic PXAs highlight a gamut of varied presentation, ranging from space occupying lesions presenting with headache and weakness to paraplegia and incontinence with an intramedullary mass; the latter being exceedingly rare 15 . Radiologically, most of our cases showed vascular, dural-based and cortical masses with some cystic changes which were known to occur 11 . Histologically, a biphasic tumour with moderate to high cellularity, pleomorphic and spindle cells, hyperchromatic nuclei showing moderate to marked atypia, intranuclear inclusions, 5-8 mitoses per 10 high-power field and foamy cytoplasm with focal evidence of necrosis and atypical mitoses were the usual pictures in most of our cases. The case showing a transformation into glioblastoma demonstrated a higher mitotic count of 8/10HPF in the primary tumour itself commensurate to the established criteria that mitotic count is the single most important predictor of the progression 3, 8, 16 . Eosinophilic granular bodies and lymphocytic infiltrates within the tumour were consistent findings. Similar morphologic observations were documented in other studies 17 . Unlike other studies, there was no distinct plane identifiable between the tumour and the brain because of the brain invasion, which was a documented feature in most of our cases 18 . Immunohistochemistry of the tumours in this series showed a more or less consistent positivity for GFAP, S100, NSE and CD34 with a significant Ki67 expression. This tumour characteristically shows the expression of glial markers such as GFAP, S100 in most cases with simultaneous expression of neuronal markers Synaptophysin and class III betatubulin as well 19 . This dual differentiation has been documented in all the cases studied along with Ki-67 labelling index, ranging from 5-20%. The PXAs show Ki67 labelling in the range less than 1%, whereas the APXAs show expression from 5-10%, which helps distinguish PXA from APXA 19 . Morphologically, APXA is a close mimic of giant-cell glioblastoma. The expression of neuronal antigens, at least focally, by the individual tumour cells in PXA contrasts against the rare expression of neuronal polypeptides by glioblastoma, the latter shows strong p53 expression 20 . APXAs are rare tumours, so little is known about their molecular profile. BRAF V600E mutation is frequent in PXA and in 65% of APXA cases 18, 21 . The expression of CD34 has been correlated with BRAF mutation in cases of PXA which have at least a focal expression in most cases within the endothelial cells as well as dysplastic cortical cells 21 . In the present series, two cases were associated with focal CD34 expression. Primary APAXs have a shorter recurrence interval than secondary APXAs; however, the latter have poorer prognosis 22 . All the five cases in the present study were primary APXA. Although one of the case studies showed a transformation into glioblastoma with evidence of spinal metastasis, all the patients are alive and on a routine postoperative follow-up. A complete surgical excision is required for a prolonged disease-free interval 5, 13 . Due to its rarity, the role of post-operative radiotherapy and chemotherapy is still not well established 1, 5 . Most of the information available about APXA comes from isolated case reports. This is one of the largest series of cases of anaplastic pleomorphic xanthoastrocytoma, compiled with an effort to understand the clinicoradiological, histopathological and immunohistochemical features.
CONCLUSION
This study highlights the importance of diversity in the clinical presentation of APXA cases as a differential diagnosis in appropriate clinicoradiological settings to perform the relevant immunologic and/or molecular studies to exclude more aggressive mimics.
